The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Enhancing treatment outcomes in RCC and NSCLC with Akkermansia supplements
Lorenzo Belluomini, PhD, University of Verona, Verona, Italy, highlights future research projects evaluating the clinical role of Akkermansia muciniphila (Akk). Previous studies has linked the abundance of Akk abundance and efficacy of checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC). Future studies assessing Akk supplements in patients with NSCLC and renal cell carcinoma (RCC) receiving checkpoint inhibitors are underway. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
